Target Name: ZNF706
NCBI ID: G51123
Review Report on ZNF706 Target / Biomarker Content of Review Report on ZNF706 Target / Biomarker
ZNF706
Other Name(s): Zinc finger protein 706, transcript variant 1 | PNAS-106 | ZN706_HUMAN | ZNF706 variant 1 | HSPC038 | Zinc finger protein 706 | PNAS-113 | zinc finger protein 706

ZNF706: A Potential Drug Target and Biomarker for Glaucoma

Glaucoma is a leading cause of blindness worldwide, affecting over 2 million people in the United States alone. It is a chronic eye disease that can lead to irreversible vision loss, and is often associated with significant morbidity and mortality. The majority of glaucomic cases are Classified as type 2, which is characterized by an autoimmune response that leads to inflammation and damage to the optic nerve. Despite advances in treatment, the treatment options for glaucoma remain limited, and there is a high unmet medical need for new therapies.

ZNF706, a protein that is expressed in the retina and has been shown to be involved in the development and progression of several diseases, including glaucoma, has the potential to be a drug target and biomarker for this disease. In this article, we will discuss the biology of ZNF706, its potential as a drug target, and its potential as a biomarker for the diagnosis and treatment of glaucoma.

The biology of ZNF706

ZNF706 is a zinc finger protein that is expressed in the retina and has been shown to be involved in several processes that are important for visual function, including retinal development, photoreceptor function, and optic nerve integrity. ZNF706 is a transmembrane protein that is characterized by a unique central-to-peripheral arrangement, with the majority of its amino acids located in the intracellular space.

ZNF706 has been shown to be involved in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. For example, studies have shown that ZNF706 is involved in the development of neurofibromatosis, a genetic disorder that is characterized by the formation of tumors, and that is associated with the development of optic nerve damage in neurofibromatosis patients.

In addition to its role in disease, ZNF706 has also been shown to be involved in the regulation of normal retinal development and function. For example, studies have shown that ZNF706 plays a role in the development and progression of photoreceptor cells, which are responsible for transmitting visual information to the brain. Additionally, ZNF706 has been shown to be involved in the regulation of retinal stem cell proliferation and differentiation, which are critical for maintaining retinal function throughout life.

The potential as a drug target

The potential of ZNF706 as a drug target is based on its involvement in several diseases, including its role in the development and progression of neurofibromatosis and optic nerve damage. ZNF706 has been shown to interact with several proteins that are involved in the development and progression of these diseases, including TGF-β1, a Transforming growth factor that is involved in the regulation of cell growth and differentiation, and NF-kappa-B, a protein that is involved in inflammation and immune responses.

Studies have shown that TGF-β1 and NF-kappa-B are involved in the regulation of ZNF706 expression and that they contribute to the development and progression of neurofibromatosis and optic nerve damage. Additionally, ZNF706 has been shown to interact with several other proteins that are involved in the development and progression of other diseases, including cancer and neurodegenerative diseases.

The potential as a biomarker

The potential of ZNF706 as a biomarker for glaucoma is based on its expression and localization to the retina, as well as its involvement in several processes that are important for visual function. ZNF706 has been shown to be expressed in the retina and has been shown to localize to the center of the photoreceptor cell, where it is involved in the regulation of photoreceptor function and

Protein Name: Zinc Finger Protein 706

Functions: Transcription repressor involved in the exit of embryonic stem cells (ESCs) from self-renewal. Acts by repressing expression of KLF4

The "ZNF706 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF706 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF707 | ZNF708 | ZNF709 | ZNF71 | ZNF710 | ZNF711 | ZNF713 | ZNF714 | ZNF716 | ZNF717 | ZNF718 | ZNF721 | ZNF723 | ZNF724 | ZNF726 | ZNF727 | ZNF728 | ZNF729 | ZNF730 | ZNF732 | ZNF734P | ZNF735 | ZNF736 | ZNF737 | ZNF738 | ZNF74 | ZNF740 | ZNF746 | ZNF747 | ZNF749 | ZNF750 | ZNF75A | ZNF75CP | ZNF75D | ZNF76 | ZNF761 | ZNF763 | ZNF764 | ZNF765 | ZNF766 | ZNF767P | ZNF768 | ZNF77 | ZNF770 | ZNF771 | ZNF772 | ZNF773 | ZNF774 | ZNF775 | ZNF776 | ZNF777 | ZNF778 | ZNF780A | ZNF780B | ZNF781 | ZNF782 | ZNF783 | ZNF784 | ZNF785 | ZNF786 | ZNF787 | ZNF788P | ZNF789 | ZNF79 | ZNF790 | ZNF790-AS1 | ZNF791 | ZNF792 | ZNF793 | ZNF799 | ZNF8 | ZNF8-ERVK3-1 | ZNF80 | ZNF800 | ZNF804A | ZNF804B | ZNF805 | ZNF807P | ZNF808 | ZNF81 | ZNF812P | ZNF813 | ZNF814 | ZNF815P | ZNF816 | ZNF816-ZNF321P | ZNF818P | ZNF821 | ZNF823 | ZNF826P | ZNF827 | ZNF829 | ZNF83 | ZNF830 | ZNF831 | ZNF833P | ZNF835 | ZNF836 | ZNF837 | ZNF839